Laura Crawley

Clinical Options for the Reduction of Elevated Intraocular Pressure

Elevated IOP in clinical practice is usually seen in glaucoma or ocular hypertension. Glaucoma affects 60 million people worldwide and 8.4 million are bilaterally blind from this chronic disease. 1 Options for reducing IOP rely on pharmacological agents, laser treatments and surgery which may be penetrating or non-penetrating. The last twenty years has seen significant changes in all of these strategies. This review aims to cover these clinical options and introduce some of the new technologies currently in development for the clinical lowering of IOP.

Recent advances in the diagnosis and management of glaucoma

Reducing intraocular pressure remains the only treatment option in glaucoma, however, prompt evaluation and management can prevent blindness and a lifetime of disability. Our Drug Review outlines the key points and recent advances in diagnosis and management.Reducing intraocular pressure remains the only treatment option in glaucoma, however, prompt evaluation and management can prevent blindness and a lifetime of disability. Our Drug Review outlines the key points and recent advances in diagnosis and management.

Recent advances in the diagnosis and management of glaucoma: Drug Review

Reducing intraocular pressure remains the only treatment option in glaucoma, however, prompt evaluation and management can prevent blindness and a lifetime of disability. Our Drug Review outlines the key points and recent advances in diagnosis and management.Reducing intraocular pressure remains the only treatment option in glaucoma, however, prompt evaluation and management can prevent blindness and a lifetime of disability. Our Drug Review outlines the key points and recent advances in diagnosis and management.

Objective Assessment of Progression after Acute Primary Angle Closure Using HRT and GDx

Irreversible damage to the optic nerve can follow the rapid increase of IOP during an Acute Primary Angle Closure (APAC). Despite the development of advanced imaging technology, there is still a lack of good longitudinal studies assessing patients after an acute attack. The aim of this study was to assess the progression of patients using different objective optic nerve head and retinal imaging parameters following APAC. Twenty patients with a single attack of APAC, were retrospectively assessed in this study. Patients were assessed with the Heidelberg Retinal Tomography (HRT3) and Scanning Laser Polarimeter (GDx-VCC) as well as Humphrey Visual Field (HVF) repeatedly up to eighteen months after the acute attack. Progression for each imaging modality was assessed with multiple parameters. All patients showed Retinal Nerve Fibre Layer (RNFL) and optic disc changes over time. At 18 months, 67% of patients showed progression in 4/5 GDx parameters, and 33% in all 5. HRT analysis similarly showed progression in 4/5 parameters in 70% of patients, and 30% in all 5. This study shows that structural progressive changes to RNFL and ONH occur following APAC confirming that APAC patients need long-term follow-up after the acute attack.